We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

32 hedge funds and large institutions have $41.9M invested in Xilio Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 32 → 32 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.02% less ownership

Funds ownership: 4.18% → 4.16% (-0.02%)

18% less capital invested

Capital invested by funds: $51M → $41.9M (-$9.05M)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
32
Holders Change
–
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
3
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$36.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.55K
3
Northern Trust
Northern Trust
Illinois
+$2.72K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$178K
2
CC
Cannell Capital
Wyoming
-$54K
3
Millennium Management
Millennium Management
New York
-$11.7K
4
Morgan Stanley
Morgan Stanley
New York
-$10.7K
5
BlackRock
BlackRock
New York
-$5.45K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$7.35M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$7.23M – – –
OCA
3
Octagon Capital Advisors
New York
$6.35M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$5M – – –
RVM
5
RiverVest Venture Management
Missouri
$3.78M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$3.77M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.33M – – –
AG
8
Artal Group
Luxembourg
$1.18M – – –
HMC
9
Harvard Management Company
Massachusetts
$1.09M – – –
TOCUITCONY
10
Trustees of Columbia University in the City of New York
New York
$654K – – –
Bank of America
11
Bank of America
North Carolina
$595K -$213 -5 -0%
SCM
12
Soleus Capital Management
Connecticut
$595K – – –
Fidelity International
13
Fidelity International
Bermuda
$573K – – –
LCM
14
Laurion Capital Management
New York
$374K – – –
BCM
15
Bridgeway Capital Management
Texas
$289K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$222K – – –
BlackRock
17
BlackRock
New York
$129K -$5.45K -128 -4%
Morgan Stanley
18
Morgan Stanley
New York
$70.8K -$10.7K -251 -12%
Renaissance Technologies
19
Renaissance Technologies
New York
$53K +$4.55K +107 +8%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$46.8K – – –
Northern Trust
21
Northern Trust
Illinois
$46.6K +$2.72K +64 +5%
State Street
22
State Street
Massachusetts
$41.1K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$34.5K -$178K -4,178 -82%
Millennium Management
24
Millennium Management
New York
$33.8K -$11.7K -275 -23%
Charles Schwab
25
Charles Schwab
California
$31.2K +$36.2K +852 New
1
2

XLO Hedge Fund Activity: Q2 2023 in Review

32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2023, worth a combined $41.9M — down 18% from $51M a quarter earlier.

Fund positioning in XLO was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 6 trimmed.

The largest buyer was Charles Schwab, opening a new position worth an estimated $36.2K. The largest seller was Citadel Advisors, cutting an estimated $178K.

  • 32 institutional investors held Xilio Therapeutics (XLO) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $41.9M of Xilio Therapeutics stock for Q2 2023, down 18% quarter-over-quarter.
  • 1 fund opened new Xilio Therapeutics positions in Q2 2023 and 1 closed out, a net change of 0 holders.
  • The largest Xilio Therapeutics buyer in Q2 2023 was Charles Schwab, an estimated $36.2K added.
  • The largest Xilio Therapeutics seller in Q2 2023 was Citadel Advisors, an estimated $178K sold.

Based on aggregated 13F filings for Q2 2023.